The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical TrialHagen Schwenzer, Sarah P. Blagden, Erica De Zan et al.|Clinical Cancer Research|2021Cited by 44
517MO Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumoursNatalie Cook, Ruth Plummer, Alastair Greystoke et al.|Annals of Oncology|2021Cited by 10
A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian CancerFarasat Kazmi, Sarah P. Blagden, Shibani Nicum et al.|Clinical Cancer Research|2021Cited by 10
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)Pavlina Spiliopoulou, Sarah P. Blagden, Farasat Kazmi et al.|Journal of Experimental & Clinical Cancer Research|2024Cited by 8
A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302).Andrew L. Coveler, T.R. Jeffry Evans, Farasat Kazmi et al.|Journal of Clinical Oncology|2021Cited by 6